Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 18/20 | 0.41 |
| ▸ | CCR2 | P41597 | 2/20 | 0.40 |
| ▸ | CACNA1F | O60840 | 3/20 | 0.39 |
| ▸ | CACNA1D | Q01668 | 3/20 | 0.39 |
| ▸ | CACNA1S | Q13698 | 3/20 | 0.39 |
| ▸ | CACNA1C | Q13936 | 3/20 | 0.39 |
| ▸ | PPARA | Q07869 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1876499 | 0.92 | TACR1 (0.40) | TACR1CCR2CACNA1FCACNA1DCACNA1S | |
| SCHEMBL1871820 | 0.88 | TACR1 (0.44) | TACR1CCR2CACNA1FCACNA1DCACNA1S | |
| SCHEMBL1876496 | 0.85 | TACR1 (0.42) | TACR1CCR2CACNA1FCACNA1DCACNA1S | |
| Hydrochloric Acid SCHEMBL1875562 | 0.83 | TACR1 (0.47) | TACR1CCR2CACNA1FCACNA1DCACNA1S | |
| SCHEMBL1876936 | 0.81 | TACR1 (0.49) | TACR1CCR2CACNA1FCACNA1DCACNA1S | |
| SCHEMBL1871100 | 0.80 | TACR1 (0.53) | TACR1CACNA1FCACNA1DCACNA1SCACNA1C | |
| SCHEMBL1877912 | 0.80 | TACR1 (0.43) | TACR1CCR2CACNA1FCACNA1DCACNA1S | |
| SCHEMBL1874416 | 0.78 | TACR1 (0.47) | TACR1CCR2CACNA1FCACNA1DCACNA1S | |
| SCHEMBL1869177 | 0.77 | TRPV1 (0.44) | TACR1CACNA1FCACNA1DCACNA1SCACNA1C | |
| SCHEMBL1868890 | 0.76 | TACR1 (0.45) | TACR1CCR2CACNA1FCACNA1DCACNA1S |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1870396-B1 | BENZYLOXYPROPYLAMINE DERIVATIVE | NIPPON ZOKI PHARMACEUTICAL CO (JP) | 2012-10-31 | — | — | EP | disclosed |
| US-7939552-B2 | Tachykinin receptor anatgonist; good transfer into blood; long half-life; stability; bradycardial agents; antiinflammatory agents ; antallergens; analgesics; antiemetics; irritable bowel disorders; skin disorders; antidepressants; antiischemic agents ; anxiolytic agents; autoimmune diseases; muscle relax | NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) | 2011-05-10 | — | — | US | disclosed |
| US-20080262230-A1 | Benzyloxypropylamine Derivative | NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) | 2008-10-23 | — | — | US | disclosed |
| EP-1870396-A1 | BENZYLOXYPROPYLAMINE DERIVATIVE | Nippon Zoki Pharmaceutical Co. Ltd. (JP) | 2007-12-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080262230-A1 | Benzyloxypropylamine Derivative | BDKRB2, BDKRB1, PNMT | TACR1 10/4885CCR2 1379/4885CACNA1F 1854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.